<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953092</url>
  </required_header>
  <id_info>
    <org_study_id>YG1699 -01</org_study_id>
    <nct_id>NCT03953092</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Youngene Therapeutics Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Youngene Therapeutics Inc., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the&#xD;
      safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple&#xD;
      ascending oral dose administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the&#xD;
      safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple&#xD;
      ascending oral dose administration.&#xD;
&#xD;
      The study consists of 2 parts: Part 1, SAD dose-escalation; Part 2, MAD dose-escalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">November 13, 2019</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single Ascending Dose and Multiple Ascending Dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events will be evaluated</measure>
    <time_frame>76 Days</time_frame>
    <description>Safety and Tolerability of YG1699</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>76 Days</time_frame>
    <description>area under the plasma drug concentration time curve from time 0 to T (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration (Cmax)</measure>
    <time_frame>76 days</time_frame>
    <description>maximum plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabete Mellitus</condition>
  <arm_group>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg YG1699 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg YG1699 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg YG1699 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YG1699</intervention_name>
    <description>YG1699 at Multiple Doses</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos</description>
    <arm_group_label>MAD Cohort 1</arm_group_label>
    <arm_group_label>MAD Cohort 2</arm_group_label>
    <arm_group_label>MAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 1</arm_group_label>
    <arm_group_label>SAD Cohort 2</arm_group_label>
    <arm_group_label>SAD Cohort 3</arm_group_label>
    <arm_group_label>SAD Cohort 4</arm_group_label>
    <arm_group_label>SAD Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are capable of giving informed consent and complying with study procedures;&#xD;
&#xD;
          2. Are between the ages of 18 and 55 years, inclusive;&#xD;
&#xD;
          3. Female subjects have a negative urine pregnancy test result at screening and Day -1,&#xD;
             and meet one of the following criteria:&#xD;
&#xD;
               1. Using a medically acceptable form of birth control for at least 1 month prior to&#xD;
                  screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral,&#xD;
                  patch, injectable or vaginal ring), implantable device (implantable rod or&#xD;
                  intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral,&#xD;
                  patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]&#xD;
&#xD;
               2. Surgically sterile for at least 3 months prior to screening by one of the&#xD;
                  following means:&#xD;
&#xD;
                    -  Bilateral tubal ligation&#xD;
&#xD;
                    -  Bilateral salpingectomy (with or without oophorectomy)&#xD;
&#xD;
                    -  Surgical hysterectomy&#xD;
&#xD;
                    -  Bilateral oophorectomy (with or without hysterectomy)&#xD;
&#xD;
               3. Postmenopausal, defined as the following:&#xD;
&#xD;
                    -  Last menstrual period greater than 12 months prior to screening&#xD;
&#xD;
                    -  Postmenopausal status confirmed by serum FSH and estradiol levels at&#xD;
                       screening;&#xD;
&#xD;
          4. Considered healthy by the Investigator, based on subject's reported medical history,&#xD;
             full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;&#xD;
&#xD;
          5. Normal renal function with estimated glomerular filtration rate (eGFR) of 60&#xD;
             ml/min/1.73m2 or greater and as deemed by the Investigator;&#xD;
&#xD;
          6. Non-smoker and no more than 2 tobacco-containing including nicotine replacement&#xD;
             products in last 6 months;&#xD;
&#xD;
          7. Body mass index (BMI) of 18.0 to 30.0 kg/m2 inclusive and body weight not less than 50&#xD;
             kg;&#xD;
&#xD;
          8. Willing and able to adhere to study restrictions and to be confined at the clinical&#xD;
             research center.&#xD;
&#xD;
          9. Male subjects with female partners of child bearing potential must agree to use&#xD;
             condoms for the duration of the study and until 12 weeks after dosing with the study&#xD;
             drug and must refrain from donating sperm for this same period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,&#xD;
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,&#xD;
             immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          2. Known or suspected malignancy;&#xD;
&#xD;
          3. History of pancreatitis or gall stones;&#xD;
&#xD;
          4. History of unexplained syncope, symptomatic hypotension or hypoglycemia;&#xD;
&#xD;
          5. Family history of long QTc syndrome;&#xD;
&#xD;
          6. History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or&#xD;
             intolerance;&#xD;
&#xD;
          7. Poor venous access;&#xD;
&#xD;
          8. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C antibody;&#xD;
&#xD;
          9. Donated or lost &gt;500ml of blood in the previous 3 months;&#xD;
&#xD;
         10. Taken an investigational drug or participated in a clinical trial within 3 months (or&#xD;
             5 half-lives), whichever is longer;&#xD;
&#xD;
         11. Taken any prescription medications within 14 days or 5 half-lives (whichever is&#xD;
             longer) of the first dose of study drug;&#xD;
&#xD;
         12. Hospital admission or major surgery within 6 months prior to screening;&#xD;
&#xD;
         13. A history of prescription drug abuse, or illicit drug use within 9 months prior to&#xD;
             screening;&#xD;
&#xD;
         14. A history of alcohol abuse according to medical history within 9 months prior to&#xD;
             screening;&#xD;
&#xD;
         15. A positive screen for alcohol, drugs of abuse at screening or Day -1;&#xD;
&#xD;
         16. An unwillingness or inability to comply with food and beverage restrictions during&#xD;
             study participation;&#xD;
&#xD;
         17. Use of over-the-counter (OTC) medication within 7 days, and herbal (including St&#xD;
             John's Wort, herbal teas, garlic extracts) within 7 days prior to dosing (Note: Use of&#xD;
             acetaminophen at &lt; 2 g/day is permitted until 24 hours prior to dosing);&#xD;
&#xD;
         18. Any condition or finding that in the Investigators opinion would put the subject or&#xD;
             study conduct at risk if the subject were to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yalin Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Youngene Therapeutics Inc., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frontage Labs</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

